The benefit of HPV vaccination

In part due to the COVID-19 pandemic, vaccination have become a hot button issue. This is true even for non-COVID vaccines that have proven significant health benefits, such as those for human papillomavirus vaccines (HPV). Although betweeen 2016 and 2021 the share of teenagers receiving their HPV vaccination series increased from 60% to 77%, Bloomberg…

What is the Enhancing Oncology Model (EOM)?

The Oncology Care Model (OCM) is dead. The Oncology Care Model was a voluntary, alternative payment model (APM), that “included financial and performance accountability for episodes of care surrounding chemotherapy administration to cancer patients.” OCM expired at the end of June 2022, and will be replaced by the Enhancing Oncology Model. EOM is a also…

Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy

That is the title of my recent paper in Advances in Therapy along with co-authors Christian Jackisch, Federico Manevy, Suzanne Frank, and Nicki Roberts. This is a case study of the fixed-dose combination therapy of pertuzumab and trastuzumab as a subcutaneous injection compared to previous treatments which were administered via infusion. The abstract is below.…

Did the Oncology Care Model produce cost savings?

The answer is ‘yes’, but the magnitude of these savings are relatively small and more than offset by additional OCM program costs. Keating et al. (2021) writes: In this exploratory difference-in-differences study of Medicare fee-for-service beneficiaries with cancer undergoing chemotherapy (483 310 beneficiaries with 987 332 episodes treated at 201 OCM participating practices and 557 354 beneficiaries with…

Goal Attainment Scaling

What outcomes should be used to measure if a medicine is a “good” medicine? Improved survival? Improved ability to function? Few side effects? Ability to get back to work? Living to attend your daughter’s wedding? All of the above? Oftentimes, health economists measure value of a treatment for the average person. Preferences for efficacy, safety,…

Large decline in cancer mortality

Last year, I published a paper that showed that cancer mortality rates fell by 24% between 2000 and 2016 and further that new cancer drugs accounted for saving 1.3 million lives in the US over that time period. At the end of the paper, we noted that these numbers may be conservative since the use…